Related Experiment Video
Updated: Jun 19, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
ADAM10 is upregulated in melanoma metastasis compared with primary melanoma
Sophia B Lee1, Anja Schramme, Kai Doberstein
1Pharmazentrum frankfurt/ZAFES, Department of Pharmacology, University Hospital Goethe, University of Frankfurt, Frankfurt am Main, Germany.
Abstract:
ADAM10 (a disintegrin and metalloproteinase 10) is involved in the ectodomain shedding of various substrates, including adhesion molecules such as L1 cell adhesion molecule (L1-CAM) and CD44, which are known to have important roles in the development of malignant melanoma. In our study, we characterized the expression of ADAM10 in melanoma cells in vitro and in vivo. Immunohistochemical analysis on tissue microarrays indicated that ADAM10 expression was significantly elevated in melanoma metastasis compared with primary melanomas. In vitro downregulation of ADAM10 with specific small interfering RNA (siRNA) resulted in a suppression of the anchorage-independent cell growth and reduced the migration of melanoma cells. In addition, overexpression of ADAM10 induced the migration of melanoma cells. In cell lines from melanoma patients with metastasis, ADAM10 was significantly overexpressed, and ADAM10 expression correlated with increased cell proliferation. Furthermore, we present evidence that ADAM10 is involved in the release of L1-CAM from melanoma cells. It is important that knockdown of cellular L1-CAM reduced the migration of melanoma cells and abrogated the chemoresistance against cisplatin. In contrast, soluble L1-CAM had no effect on melanoma cell migration or cell survival. Taken together, our data demonstrate that ADAM10 and L1-CAM have important roles during melanoma progression and both molecules represent attractive targets for therapeutical intervention of melanomas.
Insights
ADAM10 (a disintegrin and metalloproteinase 10) and L1-CAM are elevated in melanoma metastasis, driving tumor growth and migration. Targeting these molecules may offer new melanoma treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- ADAM10 (a disintegrin and metalloproteinase 10) facilitates ectodomain shedding of substrates like L1-CAM and CD44.
- L1-CAM and CD44 play roles in malignant melanoma development.
Purpose of the Study:
- To characterize ADAM10 expression in melanoma cells.
- To investigate the role of ADAM10 and L1-CAM in melanoma progression.
Main Methods:
- Immunohistochemical analysis of tissue microarrays.
- In vitro studies using small interfering RNA (siRNA) for ADAM10 downregulation.
- Overexpression studies of ADAM10.
- Analysis of L1-CAM knockdown and soluble L1-CAM effects.
Main Results:
- ADAM10 expression is significantly elevated in melanoma metastasis compared to primary melanomas.
- ADAM10 downregulation suppressed anchorage-independent growth and melanoma cell migration.
- ADAM10 overexpression increased melanoma cell migration.
- ADAM10 expression correlated with increased cell proliferation in metastatic melanoma.
- ADAM10 mediates L1-CAM release; L1-CAM knockdown reduced migration and abrogated chemoresistance.
Conclusions:
- ADAM10 and L1-CAM are crucial in melanoma progression.
- Both ADAM10 and L1-CAM represent potential therapeutic targets for melanoma treatment.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

